SAN DIEGO, June 01, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that the Company will take part in multiple investor conferences in June.
Hamza Suria, president and chief executive officer, will present a corporate overview of AnaptysBio at the Jefferies Global Healthcare Conference on Thursday, June 8, 2017 at 2:00 p.m. ET in New York City. In addition, Mr. Suria will participate in a company panel discussion titled, “Inflammation and Immunology: Restoring a Fine Balance,” at the JMP Securities Healthcare Conference on Tuesday, June 20, 2017 at 4:30 p.m. ET in New York City.
A live audio webcast of the Jefferies Global Healthcare Conference presentation will be available through the investor section of the AnaptysBio website. An archived replay will be available for 90 days following the event.
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The company’s proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody (ANB020) for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma; its anti-IL-36R antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated and have demonstrated efficacy in an animal model of graft-versus-host disease. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation (SHM) platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO and an inflammation partnership with Celgene, including an anti-PD-1 antagonist antibody (TSR-042) and an anti-TIM-3 antagonist antibody (TSR-022), which are currently under clinical development with TESARO, and an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in the clinic with Celgene. For further information, visit www.anaptysbio.com.
THRUST Investor Relations